{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:17:48Z","timestamp":1785377868863,"version":"3.55.0"},"reference-count":44,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["P30CA077598"],"award-info":[{"award-number":["P30CA077598"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Malignant melanoma is the leading cause of death due to cutaneous malignancy. Immunocompromised individuals have an elevated risk of developing melanoma. We aimed to provide histopathologic and statistical characterization of melanoma development in immunocompromised patients. Methods: We reviewed our institution\u2019s databases to identify all patients with a confirmed history of immunosuppression who subsequently developed melanoma, focusing on diagnoses during the follow-up period of 2011\u20132019. A total of 93 patients with a combined 111 melanoma lesions were identified. Results: Common causes of immunosuppression included transplantation and lymphoproliferative disorders. Superficial spreading and lentigo malignant melanoma were the most common malignant melanoma subtypes. Median Breslow depth was 0.7 mm, and the most common primary tumor stage was T1a. Our transplant sub-cohort had an overall melanoma incidence of 0.9 per 1000 person-years (95% CI 0.66 to 1.20) and a standardized incidence ratio (SIR) of 1.53 (95% CI 1.12 to 2.04) relative to a general population cohort from the Surveillance, Epidemiology, and End Results Program (SEER). Conclusions: We report histopathologic characteristics of immunocompromised patients developing melanoma at a large academic tertiary-care center. Differences in age, sex, time since transplantation, and transplant type may play a significant role in melanoma SIR in this patient demographic.<\/jats:p>","DOI":"10.3390\/cancers15143600","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:39:41Z","timestamp":1689295181000},"page":"3600","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Malignant Melanoma in a Retrospective Cohort of Immunocompromised Patients: A Statistical and Pathologic Analysis"],"prefix":"10.3390","volume":"15","author":[{"given":"Trevor F.","family":"Killeen","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Shanley","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center\u2014Biostatistics Core, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhyalakshmi","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center\u2014Clinical Informatics Shared Services, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-0662","authenticated-orcid":false,"given":"Alessio","family":"Giubellino","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"ref_1","first-page":"591","article-title":"Vital signs: Melanoma incidence and mortality trends and projections\u2014United States, 1982\u20132030","volume":"64","author":"Guy","year":"2015","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.amepre.2014.08.036","article-title":"Prevalence and Costs of Skin Cancer Treatment in the U.S., 2002\u22122006 and 2007\u22122011","volume":"48","author":"Guy","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Saginala, K., Barsouk, A., Aluru, J.S., and Rawla, P. (2021). Epidemiology of Melanoma. Med. Sci., 9.","DOI":"10.3390\/medsci9040063"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","article-title":"Treatment of Advanced Melanoma in 2020 and Beyond","volume":"141","author":"Jenkins","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/pcmr.12847","article-title":"Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma","volume":"33","author":"Lorusso","year":"2020","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2021.12.066","article-title":"Skin cancer: Primary, secondary, and tertiary prevention. Part I","volume":"87","author":"Perez","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","first-page":"71","article-title":"Melanoma susceptibility: An update on genetic and epigenetic findings","volume":"12","author":"Truderung","year":"2021","journal-title":"Int. J. Mol. Epidemiol. Genet."},{"key":"ref_9","unstructured":"American Cancer Society (2020). Key Statistics for Melanoma Skin Cancer, American Cancer Society."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaad.2015.06.052","article-title":"Immunosuppression is an independent prognostic factor associated with aggressive tumor behavior in cutaneous melanoma","volume":"73","author":"Donahue","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2012.04.018","article-title":"Melanoma in Immunosuppressed Patients","volume":"87","author":"Kubica","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cnur.2015.10.008","article-title":"Immunosuppressive Therapy in Transplantation","volume":"51","author":"Allison","year":"2016","journal-title":"Nurs. Clin. N. Am."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/312763a0","article-title":"The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus","volume":"312","author":"Dalgleish","year":"1984","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/312767a0","article-title":"T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV","volume":"312","author":"Klatzmann","year":"1984","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Olsen, C.M., Knight, L.L., and Green, A.C. (2014). Risk of Melanoma in People with HIV\/AIDS in the Pre- and Post-HAART Eras: A Systematic Review and Meta-Analysis of Cohort Studies. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095096"},{"key":"ref_16","first-page":"e13180","article-title":"Malignant melanoma in HIV: Epidemiology, pathogenesis, and management","volume":"33","author":"Rullo","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.aje.a115507","article-title":"Simple Method to Calculate the Confidence Interval of a Standardized Mortality Ratio (SMR)","volume":"131","author":"Ulm","year":"1990","journal-title":"Am. J. Epidemiol."},{"key":"ref_18","unstructured":"National Cancer Institute (2020). SEER*Explorer: An Interactive Website for SEER Cancer Statistics: Surveillance Research Program, National Cancer Institute."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1245\/s10434-020-08265-4","article-title":"Outcomes of immunosuppressed patients who develop melanoma: A population-based propensity-matched cohort study","volume":"27","author":"Austin","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jaad.2019.11.009","article-title":"Melanoma in a cohort of organ transplant recipients: Experience from a dedicated transplant dermatology clinic in Victoria, Australia","volume":"83","author":"Maor","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2015.03.045","article-title":"Cutaneous malignant melanoma in the Swedish organ transplantation cohort: A study of clinicopathological characteristics and mortality","volume":"73","author":"Krynitz","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jaad.2019.09.072","article-title":"Melanoma incidence, stage, and survival after solid organ transplant: A population-based cohort study in Ontario, Canada","volume":"83","author":"Park","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/CMR.0000000000000219","article-title":"Increased risk of melanoma in patients with chronic lymphocytic leukaemia: Systematic review and meta-analysis of cohort studies","volume":"26","author":"Olsen","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2011.34.9605","article-title":"Chronic Lymphocytic Leukemia Is Associated with Decreased Survival of Patients with Malignant Melanoma and Merkel Cell Carcinoma in a SEER Population-Based Study","volume":"30","author":"Brewer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bjh.18090","article-title":"Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study","volume":"197","author":"Jobson","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_26","first-page":"499","article-title":"Brief Report: Cutaneous Melanoma Risk Among People with HIV in the United States and Canada","volume":"78","author":"Yanik","year":"2018","journal-title":"Am. J. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jiph.2014.08.003","article-title":"Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV\/AIDS: A systematic review","volume":"8","author":"Cobucci","year":"2015","journal-title":"J. Infect. Public Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101613","DOI":"10.1016\/j.eclinm.2022.101613","article-title":"Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis","volume":"52","author":"Yuan","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jid.2022.09.008","article-title":"Risk of Nonkeratinocyte Skin Cancers in People Living with HIV during the Era of Antiretroviral Therapy","volume":"143","author":"Luu","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/archdermatol.2011.159","article-title":"Malignant melanoma in solid transplant recipients: Collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis","volume":"147","author":"Brewer","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2340\/00015555-2148","article-title":"Increased risk of melanoma in organ transplant recipients: Systematic review and meta-analysis of cohort studies","volume":"95","author":"Green","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2047-1440-3-10","article-title":"Systematic review of melanoma incidence and prognosis in solid organ transplant recipients","volume":"3","author":"Dahlke","year":"2014","journal-title":"Transplant. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/ctr.12818","article-title":"Incidence of melanoma in organ transplant recipients in Alberta, Canada","volume":"30","author":"Tran","year":"2016","journal-title":"Clin. Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Arias, E., Bastian, B., Xu, J., and Tejada-Vera, B.U.S. (2021). State Life Tables, 2018, National Center for Health Statistics (U.S.), Division of Vital Statistics.","DOI":"10.15620\/cdc:112181"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/j.1600-6143.2008.02326.x","article-title":"Melanoma in organ transplant recipients: Clinicopathological features and outcome in 100 cases","volume":"8","author":"Matin","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/ajt.12716","article-title":"Survival After Cutaneous Melanoma in Kidney Transplant Recipients: A Population-Based Matched Cohort Study","volume":"14","author":"Vajdic","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/TP.0b013e3181a238f6","article-title":"De Novo Cancers Arising in Organ Transplant Recipients are Associated with Adverse Outcomes Compared with the General Population","volume":"87","author":"Miao","year":"2009","journal-title":"Transplantation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaad.2017.10.014","article-title":"Risk of melanoma in patients with multiple myeloma: A Surveillance, Epidemiology, and End Results population-based study","volume":"78","author":"Chang","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaad.2014.09.030","article-title":"Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma","volume":"72","author":"Famenini","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/cncr.21404","article-title":"Increased incidence of melanoma in renal transplantation recipients","volume":"104","author":"Hollenbeak","year":"2005","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/ijc.24931","article-title":"Faculty Opinions recommendation of Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults","volume":"126","author":"Lanoy","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archderm.138.6.765","article-title":"Altered clinical course of malignant melanoma in HIV-positive patients","volume":"138","author":"Rodrigues","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100511","DOI":"10.1016\/j.currproblcancer.2019.100511","article-title":"The risk of melanoma in patients with chronic lymphocytic leukemia; a population-based study","volume":"44","author":"Turk","year":"2020","journal-title":"Curr. Probl. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1600-6143.2011.03565.x","article-title":"Donor-Transmitted Malignancies in Organ Transplantation: Assessment of Clinical Risk","volume":"11","author":"Nalesnik","year":"2011","journal-title":"Am. J. Transplant."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/14\/3600\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:11:58Z","timestamp":1760127118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/14\/3600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":44,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cancers15143600"],"URL":"https:\/\/doi.org\/10.3390\/cancers15143600","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]}}}